Amgen: EPS up 15% in Q4
The biotech group saw its product sales rise by 23% in volume terms, driven by double-digit growth for its Blincyto, Evenity, Repatha and Prolia products, while average selling prices contracted by 0.3%.
With full-year 2023 adjusted EPS of $18.65 and revenues of $28.2 billion, Amgen expects to achieve target ranges of $18.90-20.30 and $32.4-33.8 billion respectively for the year ahead.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction